OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for urcosimod in neuropathic corneal pain (NCP) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“We anticipate topline results from this trial in 2026, with ongoing negotiations for clinical sites.”